{
    "doi": "https://doi.org/10.1182/blood.V130.Suppl_1.2073.2073",
    "article_title": "Development and Characterization of the Novel Orally Bioavailable EZH1/2 Dual Inhibitor DS-3201 ",
    "article_date": "December 7, 2017",
    "session_type": "802. Chemical Biology and Experimental Therapeutics: Poster I",
    "abstract_text": "Polycomb repressive complex 2 (PRC2) methylates histone H3 lysine 27 (H3K27) and represses gene expression to regulate cell proliferation and differentiation. Enhancer of zeste homolog 2 (EZH2) or its close homolog EZH1 function as catalytic subunits of PRC2, so there are two PRC2 complexes containing either EZH2 or EZH1. Many reports suggest that inhibiting PRC2 activity through EZH2 knockdown gives rise to anti-cancer effect against hematological and solid cancers. To date, some EZH2 selective inhibitors have demonstrated anti-cancer potential in preclinical and clinical studies. In spite of this promise, there is concern that the efficacy anticipated with EZH2 selective inhibitors may be compromised due to compensation by EZH1 activity. Herein, we describe the novel, orally bioavailable EZH1/2 dual inhibitor DS-3201. This compound strongly and selectively inhibited the methyltransferase activity of both EZH1 and EZH2 with an IC 50 value of 10 nM and 6.0 nM, respectively in cell-free enzymatic assays. This compound also suppressed trimethylation of H3K27 in cells (IC 50 : 0.55 nM) more potently than EZH2 selective inhibitors. In order to identify the anti-cancer spectrum of DS-3201, we tested its in vitro growth inhibition activity against a panel of cancer cell lines including a variety of hematological cancers. Among the panel, hematological cell lines showed particular sensitivity to DS-3201, with GI 50 values less than 100 nM, including 1) acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) cell lines harboring fusion genes, such as MLL-AF9, MLL-AF4, or AML1-ETO, 2) diffuse large B-cell lymphoma (DLBCL) cell lines having EZH2 gain-of-function (GOF) mutations, 3) most of the peripheral T-cell lymphoma and multiple myeloma cell lines tested. Our data thus shows this compound has broader anti-cancer activity than EZH2 selective inhibitors, especially in hematology cancers. We also evaluated the in vivo anti-tumor efficacy of DS-3201 against KARPAS-422, a DLBCL tumor xenograft with an EZH2 GOF mutation. A 100 mg/kg once daily oral administration of DS-3201 caused nearly complete tumor regression without any body weight loss and 25 mg/kg administration also showed clear tumor growth delay. Based on these results, we initiated clinical studies of DS-3201 for patients with lymphoma (Clinical trial information: NCT02732275) and for those with AML and ALL (NCT03110354). Disclosures Honma: Daiichi Sankyo Co., Ltd.: Employment. Adachi: Daiichi Sankyo Co., Ltd.: Employment. Kanno: Asubio Pharma Co., Ltd.: Employment. Watanabe: Daiichi Sankyo Co., Ltd.: Employment. Hirasawa: Daiichi Sankyo Co., Ltd.: Employment. Nosaka: Daiichi Sankyo Co., Ltd.: Employment. Shiroishi: Daiichi Sankyo Co., Ltd.: Employment. Takizawa: Daiichi Sankyo RD Novare Co., Ltd.: Employment. Yasumatsu: Daiichi Sankyo RD Novare Co., Ltd.: Employment. Horiuchi: Daiichi Sankyo Co., Ltd.: Employment. Nakao: Daiichi Sankyo Co., Ltd.: Employment. Suzuki: Daiichi Sankyo Co., Ltd.: Employment. Yamasaki: Daiichi Sankyo Co., Ltd.: Employment. Nakajima: Daiichi Sankyo Co., Ltd.: Employment. Hayakawa: Daiichi Sankyo Co., Ltd.: Employment. Yamazaki: Daiichi Sankyo Co., Ltd.: Employment. Araki: Daiichi Sankyo: Employment. Fujiwara: Daiichi Sankyo Co., Ltd.: Employment.",
    "topics": [
        "acute lymphocytic leukemia",
        "administration, oral",
        "cancer",
        "catalytic domain",
        "cell lines",
        "cell proliferation",
        "complex",
        "diffuse large b-cell lymphoma",
        "disclosure",
        "employment"
    ],
    "author_names": [
        "Daisuke Honma, PhD",
        "Nobuaki Adachi, PhD",
        "Osamu Kanno, PhD",
        "Jun Watanabe",
        "Makoto Hirasawa",
        "Emi Nosaka",
        "Machiko Shiroishi",
        "Takeshi Takizawa",
        "Isao Yasumatsu",
        "Takao Horiuchi, PhD",
        "Akira Nakao, PhD",
        "Keisuke Suzuki",
        "Tomonori Yamasaki",
        "Katsuyoshi Nakajima",
        "Miho Hayakawa",
        "Takanori Yamazaki",
        "Kazushi Araki, D.V.M., PhD",
        "Kosaku Fujiwara, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Daisuke Honma, PhD",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Nobuaki Adachi, PhD",
            "author_affiliations": [
                "Biomarker Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Osamu Kanno, PhD",
            "author_affiliations": [
                "Medicinal Chemistry Function, Asubio Pharma Co., Ltd., Kobe, Japan "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jun Watanabe",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Makoto Hirasawa",
            "author_affiliations": [
                "Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Emi Nosaka",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Machiko Shiroishi",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Takeshi Takizawa",
            "author_affiliations": [
                "Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Isao Yasumatsu",
            "author_affiliations": [
                "Organic Synthesis Department, Daiichi Sankyo RD Novare Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Takao Horiuchi, PhD",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Akira Nakao, PhD",
            "author_affiliations": [
                "End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Keisuke Suzuki",
            "author_affiliations": [
                "Pain & Neuroscience Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Tomonori Yamasaki",
            "author_affiliations": [
                "Pharmacovigilance Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Katsuyoshi Nakajima",
            "author_affiliations": [
                "Venture Science Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Miho Hayakawa",
            "author_affiliations": [
                "Pharmacovigilance Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Takanori Yamazaki",
            "author_affiliations": [
                "New Drug Regulatory Affairs Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Kazushi Araki, D.V.M., PhD",
            "author_affiliations": [
                "Oncology Clinical Development Department, Daiichi Sankyo Co., Ltd., Tokyo, Japan"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Kosaku Fujiwara, PhD",
            "author_affiliations": [
                "Oncology Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-09T06:35:55",
    "is_scraped": "1"
}